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1540.59 days). CONCLUSIONS: Higher age and having arthroplasty were associated 
with increased risk of secondary hip fracture in elderly women. The higher risk of 
secondary hip fracture in patients with hip arthroplasty could be explained by their 
longer survival after primary treatment. Further analyses of risk factors are needed 
to elaborate effective prevention strategies for secondary hip fractures.
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OBJECTIVES: Bone loss is a common problem occurring among human immunode-
ficiency virus (HIV)-positive patients. Explanations for the bone loss are unknown. 
We estimated the prevalence of osteopenia among HIV-positive adults ages 18-49 
versus matched HIV-negative adults; and ranked predictors for osteopenia in terms 
of their contribution to a prediction model. METHODS: We conducted a cross-sec-
tional study on the 2005-2010 National Health and Nutrition Examination Survey 
(NHANES). HIV-positive individuals were identified according to HIV antibody test. 
Bone mineral density (BMD) T-score of femur neck was calculated based on the mean 
and SD from data for non-Hispanic white females ages 20-29 from the NHANES III. 
Osteopenia was defined as T-score between -1 and -2.5; osteoporosis was defined 
as T-score less than -2.5. A HIV-positive adult was matched with 3 HIV-negative 
adults at the same sex, age category and race. We used multiple logistic regression 
identified predictors of osteopenia among the matched cohort. RESULTS: 52 HIV-
positive individuals were identified. In the matched cohort 46 HIV-positive and 
138 HIV-negative adults were included. The mean age of the matched cohort was 
39.3±9.0 years, and 76.1% were male. No osteoporosis was observed in either case 
group or control group. The prevalence of osteopenia was 7.3% versus 1.7% among 
the cases compared to controls. Osteopenia occurred only among males in the cases 
and females in the controls. Alcohol consumption (p< 0.0001) was the strongest 
predictor of osteopenia, followed by activity intensity (p= 0.0003), family history of 
osteoporosis (p= 0.0007), and HIV itself (p= 0.0026), after controlling BMI and smoking 
status. CONCLUSIONS: HIV itself is a significant predictor for osteopenia; but due 
to lack of information on treatment history, it remains unclear if HIV medicine or 
treatment duration can increase the risk of osteopenia.
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OBJECTIVES: The risk of subsequent hip fracture is increased in presence of previous 
hip fracture. The most of the secondary hip fractures occur within the first 3 years 
after the initial hip fracture. The aim of our nationwide retrospective observational 
cohort study was to reveal the significance of demographic and clinical factors on 
time until subsequent hip fracture. METHODS: Patients aged 60 and over treated 
with primary femoral neck fractures in the year 2000 and suffered from contralateral 
hip fracture between 01 January 2000 and 31 December 2008 were selected from the 
database of the Hungarian National Health Insurance Fund. Patients’ data concern-
ing their age, gender, place of living, type of primary fracture, comorbid medical 
diseases, surgical intervention for primary fracture and hospital providing treatment 
for primary hip fracture were evaluated. Multinominal logistic regression were used 
to analyse associations between prognostic factors and the time (< 12 months, 12-24 
months, 24-36 months, 36-48 months, 48-60 months, > 60 months) until secondary 
fracture. RESULTS: 312 patients met the criteria. Having osteosynthesis as surgical 
intervention for primary fracture (osteosynthesis vs. arthroplsty, HR: 6.11, p= 0.02, 
CI: 1.28- 29.17) was significantly associated with a greater likelihood of suffering 
from secondary fracture in the fifth year than in the first year. Patients between 
60 and 69 years (60-69 years vs. > 90 years, HR: 20.95, p= 0.010, CI: 2.09- 209.44) were 
significantly more likely to have contralateral fracture in the sixth year than in the 
first year. CONCLUSIONS: First, we provide evidence of the influence of higher 
age and osteosynthesis as surgical intervention for primary fracture on the time 
until subsequent hip fractures in elderly Hungarian population. The results may 
help establish an effective strategy for the prevention of secondary hip fractures.
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OBJECTIVES: Approximately 10% of the US population is diagnosed with knee 
osteoarthritis by age 60. Disability due to arthritis increases health care costs and 
the risk of hospitalization, institutionalization, and mortality. Decreasing seden-
tary behavior can improve function and may be a modality for improving quality 
adjusted life years (QALYs). The purpose of this study was to investigate whether 
varying levels of sedentary behavior impacts the QALY differently. METHODS: This 
study used longitudinal data from the accelerometer study of the Osteoarthritis 
Initiative (OAI) collected at baseline (OAI 48-month visit) and 2-year follow-up 
(OAI 72-month visit). We restricted analyses to participants with 4-7 valid days 
of accelerometer monitoring and individuals with complete health utility data, 
yielding a sample of 1794 community dwelling adults with or at risk for radio-
graphic knee OA. QALYs (SF6D) were calculated at 48 and 72 months. Participants 
were classified into quartiles based on average daily sedentary time (most seden-
tary Q1 > = 11.6, 10.7< = Q2< 11.6, 9.7< = Q3< 10.7, least sedentary Q4< 9.7 hours). The 
association between sedentary behavior and QALYs was examined using median 
regression adjusting for age, gender, BMI. RESULTS: Average(SD) QALYs over the 
2-year follow-up were 1.56(0.23), 1.61(0.20), 1.60(0.23), 1.60(0.23) for Q1-Q4 respec-
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OBJECTIVES: Limited information exists on real-world use of biologic agents in 
ankylosing spondylitis (AS). This study evaluated the treatment patterns and costs 
of biologic therapy and disease-modifying antirheumatic drugs (DMARDs) in AS 
patients. METHODS: MarketScan claims databases were used to identify biolog-
ics treatment-naïve AS patients (≥ 18 years of age with no biologics in the past 
6 months) who initiated biologic treatment between 10/1/2009 and 09/30/2010. 
Frequency of biologic switching, duration, modification of treatment, and medical 
and pharmacy drug costs for each line of biologic therapy was analyzed during the 
3-year follow-up. RESULTS: A cohort of 339 AS patients was identified. First-line bio-
logics were: etanercept (n= 140), adalimumab (n= 137), infliximab (n= 41), golimumab 
(n= 18) and certolizumab pegol (n= 3). Approximately two-thirds of the patients 
(64.6%) discontinued their first-line biologic therapy and did not restart any biologi-
cal therapy, 23.6% of patients stayed on their first-line, 8.8% switched to second-line 
and 2.9% to third-line therapies. Patients who switched to a second- or third-line 
biologic treatment remained on their first-line agent for less time (336, 325-days, 
respectively) than those who did not switch (502-days). Most common treatment 
modifications in first-line were DMARD add-on (6.5%) and removal (5.6%). Time to 
first treatment-modification was shorter for those who switched to second- (88 
days) and third-line therapy (6-days) vs. those who remained on first-line (160-days). 
Monthly-per-member medical costs were greatest for non-switchers ($363) than for 
patients who received second-($249) or third-line ($113) treatment. Monthly-per-
member overall pharmacy drug costs were similar for patients with first-($1,908), 
second-($1,955) or third-line and above ($1,890) therapy. CONCLUSIONS: Sixty 
five percent of AS patients discontinued their first-line agent during the follow-up 
period. Those who switched biologics had more modifications to their treatment. 
Patients who switched to second- or third-line biologics had lower medical costs; 
however, their pharmacy costs were similar to those who continued their first-line.
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OBJECTIVES: Information is limited regarding the interim and long-term outcomes 
associated with knee microfracture surgery. The objective of the study was to describe 
failure rates 1 year, 3 years, and 5 years after knee microfracture surgery in an admin-
istrative claims database. METHODS: Beneficiaries with knee microfracture surgery 
between 10/1/2007 and 9/30/2008 (index surgery) and continuous enrollment 24 
months prior to the index surgery were identified in the Truven Health Marketscan® 
Commercial, Medicare Supplemental, and Medicaid databases. Patients with any knee 
procedures in the 2 years prior to index surgery were excluded. Patients were fol-
lowed for a minimum of 3 years after the index surgery and a subgroup of patients 
were followed for 5 years. Procedure failure was defined as receiving a total knee 
replacement (TKR) or revision, microfracture or autologous chondrocyte implantation 
subsequent to index surgery. RESULTS: A total of 3,498 patients (2,948 commercial 
payer, 351 Medicare and 199 Medicaid) met the study inclusion criteria. Failure rates 
increased with increasing years of follow-up: 9% within 1 year, 18% within 3 years, 
and 32% within 5 years. Among commercial payer patients, 8% were failures after 
1 year, compared to 16% after 3 years and 31% after 5 years. The highest rates of 
failure were observed among Medicare beneficiaries, in which 18%, 30%, and 41% of 
patients received knee procedures within 1 year, 3 years, and 5 years, respectively. 
Failure rates defined by TKR after microfracture surgery were 5% within 1 year, 12% 
within 3 years, and 22% within 5 years. CONCLUSIONS: Although the gold standard, 
knee microfracture surgeries have high failure rates as defined by repeat procedures 
within five years. There is a need for procedures that provide durable improvements 
in health outcomes and reduce the need for repeat interventions.
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OBJECTIVES: Hip fracture is most serious consequence of osteoporosis with sig-
nificant financial and personal costs. Our aim was to determine the significance 
of demographic and clinical factors for contralateral hip fracture among elderly 
women. METHODS: In our retrospective observational cohort study women aged 
60 years and over treated with primary femoral neck fractures in the year 2000 
were selected from the database of the Hungarian National Health Insurance Fund. 
Contralateral hip fractures were recorded between 01 January 2000 and 31 December 
2008. Patients’ data including age, place of living, hospital providing treatment for 
primary hip fracture, type of primary fracture, comorbidities, type of primary surgi-
cal intervention and survival time were studied. Prognostic factors of secondary hip 
fracture were evaluated using multivariate Cox proportional hazard regression and 
Kaplan-Meier survival analysis. RESULTS: 2866 subjects met the criteria. 263 patients 
(9.17%) suffered from secondary hip fracture during the observation period. The mean 
time until secondary fracture was 1142.82 days. Expressed as cases per person-years 
the incidence of subsequent hip fracture was 0.23. Significant correlations were found 
between higher age (years, HR: 1.03, p< 0.001, CI: 1.01- 1.05), having hip arthroplasty 
as type of surgical intervention for primary fracture (osteosynthesis vs. arthropl-
sty, HR: 1.63, p= 0.022, CI: 1.19- 2.24) and occurrence of subsequent hip fractures. 
Comparing patients’ survival on different surgical intervention, log rank test showed 
significantly longer survival (p= 0.027) in patients with arthroplasty (mean survival 
time: 1739.84 days) compared with those having osteosynthesis (mean survival time: 
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an inadequate response to methotrexate. The aim of this work is to estimate 
the budget impact of the inclusion of tofacitinib in the public list of reimburse-
ment in Colombia. METHODS: A model was built with a time horizon of three 
years. The comparators were:abatacept, adalimumab, certolizumab, etanercept, 
infliximab, golimumab, rituximab, tocilizumab, and tofacitinib. The perspective 
was of the Colombian health system including only direct costs: drug costs and 
administration costs. All currency units were in USD $ (1 USD$ = COP 1,971). A 
5% discount rate was used. The number of expected cases was calculated from 
the single national register of members of the Colombian health system (BDUA). 
Additionally a prevalence of 0.52% was used and we assumed that 30% of patients 
were refractory to initial treatment with non-biologic DMARDs. The costs of drugs 
were used current price regulation and the official database of purchase and sale 
of drugs (SISMED). The market share was estimated based on SISMED and the pro-
jected demand validated by expert physician. RESULTS: As the use of tofacitinib 
is increased from 0.9% (current scenario) to 15.3% (projected for three years) total 
spending is reduced in USD $ 80,345,510 equivalent to 5% of total expenditure of 
this pathology in Colombia. CONCLUSIONS: The use of tofacitinib in patients who 
have an inadequate response to methotrexate, decreases total costs of care for the 
health system in Colombia.
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OBJECTIVES: To conduct budget impact analysis of abobotulinumtoxinA, onabotuli-
numtoxinA, incobotulinumtoxinA in patients with post-stroke spasticity in Russia 
for 1-year period. Physical therapy was used in all therapy schemes. METHODS: A 
budget impact model was developed in Excel 2013 to simulate the costs of abobo-
tulinumtoxinA, onabotulinumtoxinA, incobotulinumtoxinA. The total number of 
patients in Russian Federation is 287,334. According to the performed modeling 
using up-to-date epidemiological data only 212,126 people survive by the 1st year 
of therapy. The following costs were taken into account:, the costs of pharmaco-
therapy, costs of inpatient and outpatient care in the Russian Federation, costs of 
adverse events, disability pensions, GDP loss due to post-stroke spasticity (PPS). 
Costs of pharmacotherapy were taken from the essential drug list and the data-
base of drugs prices. Standard of treatment of stroke consequences developed by 
Ministry of Health of the Russian Federation was used for calculation of medi-
cal care costs. Costs of adverse events were calculated basing on Russian clini-
cal guidelines and database of drugs prices. Disability pensions were taken from 
Russian Pension Fund database. GDP loss was based on the GDP information from 
World Bank. For reference, accepted exchange rate was 1 US$ = 60,29 RUB. RESULTS: 
AbobotulinumtoxinA treatment in whole population of PPS patients in Russia will 
result in US$ 185,07 million economy for 1 year compared with onabotulinumtoxinA, 
US$ 183,13 million economy compared with IncobotulinumtoxinA and will result in 
US$ 756 economy for 1 year compared with onabotulinumtoxinA, US$ 737 economy 
compared with incobotulinumtoxinA per one patient. This cost reduction is mainly 
attributed to decrease of GDP loss, disability pensions due to the better efficacy of 
this BTA drug. CONCLUSIONS: Inclusion of abobotulinumtoxinA therapy is the most 
cost saving treatment option in the management of post-stroke spasticity in Russia 
compared with other BTA medications.
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OBJECTIVES: A number of therapeutic classes are available to treat psoriatic 
arthritis (PsA), including biologic drugs. Although the wholesale acquisition cost 
of biologic drugs has increased in recent years, there is little published evidence 
documenting cost trends from the US perspective. The objective of this study was 
to assess cost trends for patients using biologic therapy for PsA from the US per-
spective. METHODS: Continuously enrolled adult patients with ≥ 2 outpatient 
diagnoses of PsA were selected from the MarketScan databases if their first bio-
logic prescription date (index date) occurred between July 1, 2008, and July 31, 2013. 
Patients were included in the study if (1) full access was available to all medical 
and pharmacy claims for ≥ 6 months before and ≥ 12 months after their index date, 
and (2) they were biologic-naïve before index. Healthcare costs were assessed from 
the payer perspective and based on annual reimbursed amounts. Results were 
stratified by all-cause vs. PsA-related costs and within these 2 categories further 
subdivided into medical inpatient, medical outpatient, emergency room, and phar-
macy costs. RESULTS: In total, 25,565 patients met the inclusion criteria. All-cause 
healthcare costs in the 6 annual cohorts increased by 53.1% between 2008 and 
2013, with an average annual increase of 10.6% (or $2,867). PsA-related annual costs 
were estimated to increase by 63.6%, with an average annual increase of 12.7% (or 
$2,335). Although cost increases in all categories of interest were observed over 
time, the major driver of the observed trends was the PsA-related pharmacy costs, 
predominantly the cost of biologic therapy, with an estimated increase of 65.6% and 
an average annual increase of 13.1% (or $2,220). CONCLUSIONS: For US managed 
care payers, total healthcare costs among patients initiated on biologic therapy for 
PsA has increased by 53.1%, which is mostly driven by the 65.6% change in PsA-
related pharmacy costs.
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tively. QALYs were significantly lower for the most sedentary (Q1) group relative 
to the two least sedentary groups (Q3 and Q4) adjusted for age, gender, and BMI. 
Furthermore, for average overweight women age 65, every additional hour spent 
in sedentary behavior was associated with greater decreases in median QALYs for 
those who were more sedentary than those who were less sedentary (Q1: -0.049, 
95%CI: -0.074, -0.025; Q2: -0.058, 95% CI: -0.135,0.019; Q3: -0.031, 95% CI: -0.092,0.030; 
Q4: 0.01, 95% CI: -0.006,0.032). CONCLUSIONS: Persons in the most sedentary group 
suffered the greatest QALY losses. Study results support interventions targeting the 
most sedentary persons in reducing this behavior.
MuScular-Skeletal dISorderS – cost Studies
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OBJECTIVES: To assess the validity of a previously published, updated denosumab 
budget impact model (BIM), evaluating the budgetary impact to a hypothetical US 
health plan of increased utilization of denosumab in postmenopausal women with 
osteoporosis at high risk of fracture. METHODS: The BIM was evaluated using face 
validity, internal validity and cross validity tests. Face validity of the model was 
assessed by comparing the underlying Markov model with prior published osteopo-
rosis cost-effectiveness studies and osteoporosis reference model. Internal validity 
was assessed using: 1) extreme value analyses on input parameters; and 2) two-way 
sensitivity analyses by simultaneously varying the market share, price of deno-
sumab, and direct medical costs of fractures. Cross validity tests were conducted on 
the following input parameters: population parameters, treatment persistence rate 
and direct medical costs of fractures. RESULTS: In a base case analysis, increasing 
utilization of denosumab up to 19.6% of eligible patients in year 3 compared with a 
constant 16% in years 1 through 3, resulted in a net per-member-per-month (PMPM) 
of < $0.0025 in each year. The use of a well-validated osteoporosis Markov model 
with health states aligned with osteoporosis reference model suggests face validity 
for the BIM. The results of the BIM model varied in expected directions in internal 
validity tests: extreme value analysis showed the model was sensitive to the pro-
portion of population currently or newly treated with osteoporosis medication. In 
the two-way sensitivity analyses, the PMPM increased with increases in price and 
market share of denosumab. The input parameters used in the model fell within the 
ranges published in literature, thus providing cross validity. CONCLUSIONS: The 
current study showed that the denosumab BIM is well validated and can serve as a 
useful tool to assess the potential impact to a US health plan’s budget of increased 
denosumab utilization in postmenopausal osteoporosis.
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OBJECTIVES: Upper limb spasticity (ULS) secondary to stroke has a considerable 
patient and caregiver burden, particularly with regards to pain, activities of daily 
living and mobility. Botulinum neurotoxin-A (BoNT-A) injections are effective in 
treating ULS. We aimed to calculate annual cost per-patient basis and the expected 
overall annual budget impact in Hong Kong using static and dynamic market share 
scenarios. METHODS: A budget impact model for BoNT-A use, adopting a Hong 
Kong healthcare system perspective, was developed. Two market-share scenarios 
were modelled over 5 years. While the static scenario assumed current market 
shares (abobotulinumtoxinA, 24%; onabotulinumtoxinA, 76%) to remain constant 
over time, the dynamic scenario assumed market share of abobotulinumtoxinA 
to rise up to 65% across 5 years. Epidemiologic data inputs were sourced from the 
most recently published literature, unit costs for BoNT-As, healthcare resources use 
from physicians working in Hong Kong, and market share assumptions from IMS 
Health (Market Sizing). Equivalence of the 2 BoNTAs in terms of efficacy and safety 
is assumed but the units of abobotulinumtoxinA are specific to the preparation 
and are not interchangeable with other preparations of botulinum toxin. RESULTS: 
Annual cost per ULS patient were 59 907 HKD, and 76 888 HKD respectively, with 
prescribing patterns following SmPC recommendations for abobotulinumtoxinA 
and onabotulinumtoxinA. The annual budget impact was decreased by between 28 
731 553 HKD in year 2 and 111 142 610 HKD in year 5 by shifting the market share 
to abobotulinumtoxinA. Sensitivity analyses showed that time to re-injection, and 
dose per injection for both toxins were the most influential parameters on budget 
impact, impacting both drug acquisition costs and physician visits. CONCLUSIONS: 
Increased use of abobotulinumtoxinA relative to onabotulinumtoxinA could poten-
tially reduce the total cost of treating ULS patients in Hong Kong.
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OBJECTIVES: Tofacitinib is an oral small molecule Janus kinase inhibitor for the 
treatment of moderate to severe rheumatoid arthritis (RA) in adults who have 
